Robert B. DuBridge

5.2k total citations · 2 hit papers
26 papers, 2.9k citations indexed

About

Robert B. DuBridge is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Robert B. DuBridge has authored 26 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 10 papers in Oncology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Robert B. DuBridge's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Virus-based gene therapy research (6 papers) and CRISPR and Genetic Engineering (6 papers). Robert B. DuBridge is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Virus-based gene therapy research (6 papers) and CRISPR and Genetic Engineering (6 papers). Robert B. DuBridge collaborates with scholars based in United States. Robert B. DuBridge's co-authors include M P Calos, Po-Cheng Tang, J H Miller, Marcia Stickler, Fiona Harding, Michèle P. Calos, Jeffrey H Miller, Phaik‐Mooi Leong, Peter H. Tang and Kay S. Greisen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Robert B. DuBridge

26 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.

1987 967 citations Robert B. DuBridge, M P Calos et al. Molecular and Cellular Biology profile →
The immunogenicity of humanized and fully human antibodies

2010 550 citations Fiona Harding, Marcia Stickler et al. mAbs profile →

Peers

Countries citing papers authored by Robert B. DuBridge

Since Specialization

Citations

This map shows the geographic impact of Robert B. DuBridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert B. DuBridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert B. DuBridge more than expected).

Fields of papers citing papers by Robert B. DuBridge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert B. DuBridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert B. DuBridge. The network helps show where Robert B. DuBridge may publish in the future.

Co-authorship network of co-authors of Robert B. DuBridge

This figure shows the co-authorship network connecting the top 25 collaborators of Robert B. DuBridge. A scholar is included among the top collaborators of Robert B. DuBridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert B. DuBridge. Robert B. DuBridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager 2022 ·Biochemistry and Biophysics Reports ·(unknown), Patricia Culp, Robert B. DuBridge, Tseng-hui Timothy Chen	3
2	Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186 2022 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), (unknown), Jeremiah D. Degenhardt, (unknown), Pui Seto, Jessica Krakow, Russell Wall, Brian J. Hillier, Ying Zhu, Maia Vinogradova, Robert B. DuBridge, Chad May	10
3	Structural arrangement of the VH and VL domains in the COBRA™ T-cell engaging single-chain diabody 2021 ·PubMed ·Jessica Krakow, Michal Hammel, Ying Zhu, Brian J. Hillier, (unknown), (unknown), (unknown), Tseng-hui Timothy Chen, (unknown), (unknown), Robert B. DuBridge, Maia Vinogradova	1
4	COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors 2020 ·mAbs ·(unknown), Pui Seto, Russell Wall, Brian J. Hillier, Ying Zhu, Jessica Krakow, (unknown), (unknown), (unknown), Tseng-hui Timothy Chen, Jeremiah D. Degenhardt, Patricia Culp, (unknown), Maia Vinogradova, Chad May, Robert B. DuBridge	41
5	Deep mutational scanning of an antibody against epidermal growth factor receptor using mammalian cell display and massively parallel pyrosequencing 2013 ·mAbs ·C.M. Forsyth, Veronica Juan, Yoshiko Akamatsu, Robert B. DuBridge, (unknown), Alexander Ivanov, (unknown), (unknown), (unknown), Keith E. Wilson, David B. Powers	49
6	Affinity and Cross-Reactivity Engineering of CTLA4-Ig To Modulate T Cell Costimulation 2012 ·The Journal of Immunology ·(unknown), Veronica Juan, Alexander V. Ivanov, (unknown), (unknown), David B. Powers, Robert B. DuBridge, Keith E. Wilson, Yoshiko Akamatsu	19
7	The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site 2011 ·Genes and Immunity ·Marcia Stickler, (unknown), (unknown), Paul R. Hinton, Robert B. DuBridge, Fiona Harding	11
8	Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms 2010 ·Clinical Cancer Research ·Patricia Culp, Donghee Choi, Yongke Zhang, Johnny Yin, Pui Seto, Suzanne E. Ybarra, (unknown), Mien Sho, Roxanne Steinle, Melanie Wong, (unknown), Jennifer Grove, (unknown), (unknown), Eric D. Hsi, Debra T. Chao, David B. Powers, Vanitha Ramakrishnan, Robert B. DuBridge	62
9	Consistency of a two clinical site sample collection: A proteomics study 2010 ·PROTEOMICS - CLINICAL APPLICATIONS ·(unknown), Charles Hannum, Karen L. Reckamp, Robert A. Figlin, Robert B. DuBridge, Sushmita Roy, Shanhua Lin, Christopher H. Becker, (unknown), (unknown), John C. Cheville, Keith E. Wilson	5
10	The immunogenicity of humanized and fully human antibodies breakdown → 2010 ·mAbs ·Fiona Harding, Marcia Stickler, (unknown), Robert B. DuBridge	550
11	Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits 2007 ·Investigational New Drugs ·Vinay Bhaskar, Melvin Fox, (unknown), Melanie Wong, Pauline Wales, Susan Rhodes, Robert B. DuBridge, Vanitha Ramakrishnan	44
12	A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo 2007 ·Journal of Translational Medicine ·Vinay Bhaskar, Dong Zhang, Melvin Fox, Pui Seto, Melanie Wong, Pauline Wales, David B. Powers, Debra T. Chao, Robert B. DuBridge, Vanitha Ramakrishnan	66
13	Identification and validation of anti-TMEFF2-Auristatin E conjugated antibodies in the treatment of prostate cancer 2004 ·Journal of Clinical Oncology ·Debbie A. Law, Daniel Afar, Vinay Bhaskar, (unknown), Rick Powers, (unknown), Melanie Wong, Robert B. DuBridge, Vanitha Ramakrishnan, Robin Murray	1
14	Increased thrombin responsiveness in platelets from mice lacking glycoprotein V 1999 ·Proceedings of the National Academy of Sciences ·Vanitha Ramakrishnan, (unknown), Francis DeGuzman, Usha Deshpande, (unknown), Robert B. DuBridge, David R. Phillips	74
15	Recombinant shuttle vectors for the study of mutation in mammalian cells 1988 ·Mutagenesis ·Robert B. DuBridge, Michèle P. Calos	56
16	Analysis of Mutation in Human Cells by Using an Epstein-Barr Virus Shuttle System 1987 ·Molecular and Cellular Biology ·Robert B. DuBridge, Peter H. Tang, (unknown), Phaik‐Mooi Leong, Jeffrey H Miller, Michèle P. Calos	465
17	Molecular approaches to the study of gene mutation in human cells 1987 ·Trends in Genetics ·Robert B. DuBridge, Michèle P. Calos	12
18	Amplification of a bovine papillomavirus-simian virus 40 chimera 1985 ·Journal of Virology ·Robert B. DuBridge, Monika Lusky, Michael R. Botchan, M P Calos	8
19	Transfected DNA is mutated in monkey, mouse, and human cells. 1984 ·Molecular and Cellular Biology ·Jane Lebkowski, Robert B. DuBridge, (unknown), Kay S. Greisen, M P Calos	125
20	Transfected DNA Is Mutated in Monkey, Mouse, and Human Cells 1984 ·Molecular and Cellular Biology ·Jane Lebkowski, Robert B. DuBridge, (unknown), Kay S. Greisen, Michèle P. Calos	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact